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Abstract
Introduction: Despite continued improvements in diagnosis, surgical techniques, and chemotherapy, breast cancer
patients are still overcome by cancer metastasis. Tumor cell proliferation, invasion and metastasis are mediated, at
least in part, through degradation of basement membrane by neutral matrix metalloproteinases (MMP) produced
by tumor and stromal cells. Evidence suggests that MMP-9 plays a significant role in breast tumor cell invasion and
metastasis. DNAzymes or catalytic oligonucleotides are new classes of gene targeting molecules that bind and
cleave a specific mRNA, resulting in decreased protein expression.
Methods: The application of anti-MMP-9 DNAzyme (AM9D) for the treatment of primary and metastatic breast
cancer was evaluated in vitro and in vivo using MDA-MB-231 cells and the MMTV-PyMT transgenic breast cancer
mouse model. Spontaneously developed mammary tumors in MMTV-PyMT transgenic mice were treated
intratumorally with naked AM9D, once a week for 4 weeks. The stability of DNAzyme was determined in vitro and
in vivo using fluorescently labeled DNAzyme.
Results: AM9D specifically inhibited expression of MMP-9 in MDA-MB-231 cells resulting in reduced invasive
property of these cells by 43%. Weekly intratumoral treatment of spontaneously developed mammary tumors in
MMTV-PyMT transgenic mice was sufficient to significantly reduce the rate of tumor growth and final tumor load
in a dose dependent and statistically significant manner (P < 0.05). This decrease in tumor growth was correlated
with decreased MMP-9 protein production within the treated tumor tissues. Tumors treated with AM9D were also
less vascularized and contained more apoptotic cells compared to control and untreated tumors.
Conclusions: These results show that targeting and down regulation of MMP-9 by AM9D could prove useful as a
therapy against breast carcinoma tumor growth and invasion.
Introduction
Breast cancer is one of the leading causes of cancer death
in women, second only to lung cancer [1-3]. The majority
of morbidity and mortality amongst cancer patients is
due to metastasis of tumor cells to distant organs [2,4].
Breast cancer most commonly metastasizes to bone,
lymph nodes, lung, liver, and brain [5]. Despite continued
improvements in diagnosis, surgical techniques, and che-
motherapy, lethality from breast cancer remains high.
Matrix metalloproteinase-9 (MMP-9) production by
tumor and stromal cells is one of the most important
factors for metastatic behavior of tumor cells [6-8].
MMP-9 is a member of the metzincin family of
enzymes, which play an important role in normal phy-
siological responses, including wound healing and bone
formation [9]. MMP-9 becomes deregulated during
tumorigenesis and is associated with pro-oncogenic
events such as neo-angiogenesis, tumor cell proliferation
and metastasis [10]. High level of MMP-9 expression in
breast cancer is positively correlated with enhanced
tumor cell invasion and metastasis [11,12] and with
enhanced progression and poorer prognosis [10].
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MMP-9 is conserved across several species (human,
chimpanzee, dog, cow, mouse, rat, chicken, zebrafish,
and Arabidopsis thaliana). MMP-9 degrades type IV
collagen, one of the most abundant collagens in the
extracellular matrix (ECM) [13], which may stimulate
local invasion, the first step in metastasis. In addition,
MMP-9 also cleaves pro-cytokines, chemokines, and
growth factors, thereby modifying their biological activ-
ity [14-16]. The downregulation of MMP-9 has been
shown to increase b1-integrin expression, leading to
activation of extracellular signal-regulated kinases
(ERKs) and increasing apoptosis through one of two
mechanisms: (1) release of cytochrome C into the cyto-
sol and/or (2) increase in nuclear factor-B (NF-B)
activation, followed by activation of caspase-3 [17].
Although few normal cell types express MMP-9 under
normal physiological conditions, the majority of human
metastatic tumor cells that have been tested consistently
show elevated MMP-9 activity compared with benign
control cells, including melanoma, fibrosarcoma, breast
adenocarcinoma, and glioma [18-21]. In addition, tumor
cells that stably express MMP-9 cDNA have been
shown to have enhanced metastastic ability [22]. Thus,
inhibition of MMP-9 expression could be a useful thera-
peutic modality to decrease the growth and invasive
properties of tumor cells.
RNA-cleaving phosphodiester-linked DNA based
enzymes (DNAzymes) are catalytic DNA molecules that
specifically bind to and cleave targeted mRNA in a
sequence-specific manner. The result is efficient degra-
dation of the mRNA transcript, and thus, similar
decreased expression levels of the encoded protein
[23,24]. Catalytic oligonucleotides have emerged as
novel, highly selective inhibitors or modulators of gene
expression [25]. Khachigian and colleagues have
reported that the DNAzymes targeting early growth
response factor-1 (Egr1) mRNA inhibit neointimal for-
mation after balloon injury to the rat carotid artery wall
and reduce intimal thickening after stenting of pig cor-
onary arteries [26]. DNAzyme targeting c-Jun causes
repair of injured carotid arteries in rats [27]. Finally, a
DNAzyme targeting vascular endothelial growth factor
receptor 2 (VEGFR2) significantly inhibits the growth of
breast tumors derived from xenografting of MDA-MB-
435 cells into nude mice by inducing apoptosis [28].
Here, we examine the effects of a novel anti-MMP9
DNAzyme (AM9D) on breast tumor growth in the
mouse mammary tumor virus-driven polyoma virus
middle T oncoprotein transgenic (MMTV-PyMT)
mouse model of breast cancer. We demonstrate for the
first time that once-weekly intratumoral injection of
AM9D in the absence of any carrier molecule, for four
weeks, was sufficient to significantly reduce the rate of
tumor growth and final tumor load in a dose-dependent
and statistically significant manner (P ≤0.05). Together,
the data presented here justify the further development
of AM9D for its potential as an anti-tumor agent and as
an ideal candidate for breast cancer therapy.
Materials and methods
DNAzyme
All DNA oligonucleotides used in these experiments
were synthesised by Integrated DNA Technology (Coral-
ville, IA, USA). DNAzymes were designed according to
the specific rule of 10-23 DNAzyme [29]. The DNA-
zyme targeting MMP9 mRNA contains a catalytic
domain of 15 highly conserved deoxynucleotides flanked
by two substrate-recognition domains. The sequence of
the DNAzyme targeting mRNA of mouse and human
MMP-9 is 5’-GTGGTGCCAGGCTAGC TACAAC-
GATTGAGGTCG-3’. In the control DNAzyme, 5’-
CTAGTCAGCGGCTAGCTACAACGATAAGCTGCT-
3’, the catalytic sequence of DNAzyme is flanked by
nine bases randomly chosen and not specific for any
MMP coding sequence. In some cases, the DNAzyme
was end-labeled with Alexa Fluora C5-melamide 633 or
Oregon Green™ 488 C5-maleimide (Invitrogen, Carls-
bad, CA, USA) using T4 Polynucleotide kinase, as sug-
gested by the manufacturer’s protocol.
Cell transfection
MDA-MB-231 human breast tumor cell lines (ATCC,
Manassas, VA, USA) were plated in DMEM supplemen-
ted with 10% fetal bovine serum (FBS) and allowed to
grow to 80 to 90% confluence at 37°C with 5% CO2. The
cells were then serum-starved for 4 hours prior to transi-
ent transfection with Oregon Green™488-maleimide-
labeled AM9D or control DNAzyme (24 μg) using Lipo-
fectamine 2000 (Invitrogen). After 18 hours incubation at
37°C in serum-free medium, cells were collected and
sorted, and the transfected cells were isolated for further
analysis.
Analysis of MMP9, MMP1, MMP13, MMP14, MMP19 and
MMP21 mRNA levels in transfected cells
The MMP9, MMP1, MMP13, MMP14, MMP19 and
MMP21 mRNA expression levels in the DNAzyme-
transfected cells were quantified by reverse transcrip-
tion-polymerase chain reaction (RT-PCR) using specific
MMP9 (forward primer; 5-GCAGGAATGCGGCTCT
GG-3’, reverse primer; 5’-CCCGTCGAAGGGATACC-
3’), MMP1 (forward primer; 5’-CATTCTACTGA-
TATCGG-3’, reverse primer; 5’-AGAAAACAGAAAT-
GAAA-3’), MMP13 (forward primer; 5-GAC TTCCCA
GGAATTGGTGA-3, reverse primer; 5-TGA CGCGAA-
CAATACGGTTA-3’), MMP14 (forward primer; 5’-
GAGCTCAGGGCAGTGGATAG -3’, reverse prime; 5’-
CCACCTCAATGATGATCACC -3’), MMP19 (forward
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primer; 5’-GGGTCCTGTTCTTCCTACAT-3’, reverse
primer; 5 CAATCCTGCAGTACTGGTCT-3’), and
MMP21 (forward primer; 5’-AACAATAGGACACGC-
TATGG-3’, reverse primer; 5’-CATCTCTTTTC-
CATGTCCAG-3’) primers [30]. Total RNA from the
transfected cells was isolated by Trizol reagent (Invitrogen)
and reverse-transcribed with random hexamer primers
(Promega, Madison, WI, USA) using MMLV-RT enzyme
(Invitrogen, Carlsbad, CA).
Mouse or human BACT (b-actin) mRNA was also
amplified as internal controls, with corresponding
(human forward; 5’-CAAGAGATGGCCACGGCGGCT-
3’, human reverse; 5’-TCCTTCTGCATCCTGTCAGCA-
3’, mouse forward; 5’-CAGGAGATGGCCACTGCCG
CA-3’, mouse reverse; 5’-AAGCACTTGCGGTGCAC-
GATG-3’) primers. The PCR products were subjected to
2% agarose gel and visualized by ethidium bromide
staining. Expression was quantified by an Alpha Imager
2000 documentation and analysis system (Alpha Inno-
tech Corporation, San Leandro, CA, USA).
Analysis of MMP-9 activity by gelatin gel zymography
MDA-MB-231 cells were transiently transfected with
AM9D or control DNAzyme in serum-free medium as
stated above. Twenty-four hours post transfection-media
were collected and concentrated 10-fold using Amicon
Ultracell filtration units (Millipore, Co Cork, Ireland).
Protein concentration of the collected media was deter-
mined by Bradford dye binding techniques (a standard
Bio Rad assay) using bovine serum albumin as a stan-
dard. The MMP-9 activity in the culture media was
then assessed by gelatin zymography [31].
Cell invasion assay
Cells were transfected with fluorescently labeled AM9D or
control DNAzyme for 18 hours in serum-free media as
above. The fluorescent positive cells were identified by flow
cytometry, isolated and seeded in ECMatrix™invasion
chambers (Millipore, Billerica, MA, USA). After 24 hours
incubation at 37°C with 5% CO2, the number of cells that
migrated through the ECM layer and attached to the poly-
carbonate membrane was quantified spectrophotometeri-
cally at 560 nm according to the manufacturer’s protocol.
The assays were done in multiples and the differences in
the values between groups were evaluated by analysis of
variance (ANOVA). P <0.05 was considered significant.
In vitro stability of DNAzyme
AM9D was incubated in PBS at 37ºC, and an equal
amount was removed at various time points and incubated
with MMP9 mRNA at 37ºC. After a 2-hour incubation the
RNA samples were visualized on a 4% urea-polyacrylamide
gel. For DNAzyme cellular uptake and stability, MDA-
MB-231 cells were cultured on cover-glass slides. Cells
were then transfected with 4 µg fluorescently labeled
DNAzyme, as described above, fixed with formaldehyde at
24, 48, or 72 hours post transfection and visualized by
confocal microscopy. The nucleus was visualized by 4’,6-
diamidino-2-phenylindole (DAPI)/anti-fade.
Animals
All animal experiments were conducted following
approval by the University of Tennessee Health Science
Center Institutional Animal Care and Use Committee
(IACUC). Friend virus B-type (FVB)/Nj female mice were
obtained from Jackson Laboratory (Bar Harbor, ME,
USA) and crossed with PyMT-positive FVB males. The
offspring were genotyped by real-time PCR on a Roche
LC 480 LightCycler using the following primers and uni-
versal probe library (UPL) probe #11 (forward primer: 5’
AACCCGAGTTCTCCAACAG 3; reverse primer: 5’
TCAGCAAC ACAAGGATTTC 3’) to identify MMTV-
PyMT-positive females. Female mice were palpated once
a week beginning at approximately 4 weeks of age and
palpable tumors were measured in two dimensions (long-
est diameter and shortest width) with digital calipers.
Tumor volume was calculated using the formula:
Tumor volume = Width2 × Length/2
When each transgenic female developed at least three
palpable tumors of dimensions of 3 mm × 5 mm, which
typically occurred at 8 weeks of age, each tumor was
injected intratumorally with either 10 or 25 µg of
AM9D or control DNAzyme suspended in PBS in a
total volume of 5 µl, using a Hamilton syringe mounted
with a PT2, 26G needle. Tumors identified at week 0
were injected once per week for a total of 4 weeks of
therapy, and the site of intratumoral injection was varied
to ensure that all areas of the tumor were exposed to
the AMD9 or control DNAzyme. Palpable mammary
tumors that arose after week 1 in other mammary
glands of the same mice were left untreated. For each
cohort, transgenic females with a combined number of
at least nine tumors of comparable size were utilized
(AMD9, 25 μg, n = 2 mice and 12 mammary tumors
and control DNAzyme, n = 3 mice and 9 mammary
tumors). An independent cohort of animals was also
included in tumor endpoint volume studies, in which
additional mice were treated with either control DNA-
zyme (25 µg, n = 3 mice and 15 mammary tumors) or
AM9D (AM9D, 10 µg, n= 2 mice and 9 mammary
tumors; 25 µg, n = 2 mice and 9 mammary tumors).
Tumor growth was monitored weekly by caliper mea-
surement. All animals were euthanized one week after
the last DNAzyme treatment (typically at 12 weeks of
age). At necropsy, tumors were removed, final tumor
dimensions were measured by calipers and the tumor
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wet weight was determined. Tumors were then either
flash frozen in liquid nitrogen, or fixed in 4% parafor-
maldehyde overnight, followed by cryoprotection in 25%
sucrose for several days. Cryoprotected tumors were
then washed with 0.1% PBS prior to embedding in opti-
mal cutting temperature (OCT) compound and prepara-
tion of 8-micron sections.
For analysis of Mmp9 mRNA expression levels in
tumors, OCT compound-embedded tumor sections
were scraped from glass slides of individual control
DNAzyme or AM9D-treated tumors to form a pool of
tumor material, and total RNA and cDNA was prepared
and analyzed by RT-PCR analysis as described above.
Immunohistochemistry
Mammary tumor vasculature was visualized using rat
anti-mouse CD31 antibody (1:50) (BD Biosciences, San
Jose, CA, USA) and Alexa Fluor-594 goat anti-rat IgG (H
+L) secondary antibody (Invitrogen). Stromal cells (myo-
fibroblasts) were detected using anti-a-smooth muscle
actin (a-SMA) antibody at 1:250 dilution (Sigma, St.
Louis, MO) and Alexa Fluor 488 goat anti-mouse IgG2a
(Invitrogen) secondary antibody at 1:500 dilution. MMP-
9 protein was detected using a rabbit anti-mouse MMP-9
antibody at a 1:200 dilution (Santa Cruz Biotechnology,
Santa Cruz, CA) followed by Alexa Fluor-594 goat anti-
rabbit IgG antibody (1:500). Digital images were captured
using a Bio-Rad Confocal Laser Scanning Microscope,
using the Lasersharp 2000 software. Image J imaging ana-
lysis software was used for measurement of MMP-9,
CD31-immunostained endothelial area (EA), and cas-
pase-3-positive cells in the scanned immunohistochemis-
try (IHC) sections of mammary tumors. According to
Chantrain et al. [32], compared with the so-called hot
spot and the random fields methods, the EA measure-
ment method is more reproducible for quantification of
tumor vasculature.
Statistical analysis
All data are expressed as mean ± SD or standard error
(SE). Data were analyzed with SSPS software (SigmaStat
version 2.03) using one-way analysis of variance
(ANOVA), or Student’s t-test. Tumor growth over time
among three groups was analyzed by two-way ANOVA
using Prism software (Graphpad version 4.0b, La Jolla,
CA). In all cases, P-values <0.05 were considered statis-
tically significant.
Results
AM9D treatment specifically reduces MMP-9 production
and suppresses the invasive behavior of breast tumor
cells in vitro
The specificity of AM9D toward MMP9 mRNA was
demonstrated in MDA-MB-231 human breast cancer
cells. MDA-MB-231 cells express MMP1, MMP9,
MMP13, MMP14, MMP19, and MMP21 (Figure 1A,
lane 3). As shown in Figure 1A and 1B, contrary to con-
trol DNAzyme (lane 2), AM9D treatment (lane 1) signif-
icantly decreased the activity (Figure 1B) and the level of
MMP9 mRNA (Figure 1A) in MDA-MB-231 cells
Figure 1 Effect of AM9D treatment on metalloproteinase (MMP) expression in MDA-MB-231 cells. (A) Expression levels of MMP9, MMP1,
MMP13, MMP14, MMP19, and MMP21, and BACT (ß-actin) mRNA in MDA-MB-231-transfected cells. MDA-MB-231 cells were transfected with
Oregon Green 488-labeled DNAzymes, control DNAzyme or mock transfection reagents as described in Materials and methods. Positively
transfected cells were identified by flow cytometry. Total RNA was isolated and MMP9, MMP1, MMP13, MMP14, MMP19 and MMP21, and BACT (ß-
actin) mRNA were amplified by reverse-transcription (RT)-PCR and the PCR products were subjected to agarose gel and visualized by ethidium
bromide staining. Lane 1, AM9D; lane 2, control DNAzyme; lane 3, cells treated with DOTAP (N-[1-(2,3-Dioleoyloxy)]-N,N,N-trimethylammonium
propane methylsulfate) transfection reagent only. (B) Gelatin zymography of culture media from transfected MDA-MB-231 cells. The cultured
media from MDA-MB-231 cells transfected with AM9D (lane 1), control DNAzyme (lane 2), or treated with DOTAP alone (lane 3) were separated
on 8% SDS polyacrylamide gel containing 1 mg/ml gelatin. (C) Histogram showing the percentage of carcinoma cells invading the ECMatrix™
matrigel matrix after treatment with AM9D compared to cells treated with control DNAzyme. Cells were transfected with Oregon Green 488
labeled-DNAzymes, sorted and cultured in a matrigel matrix invasion chamber as described in Materials and methods. *P <0.05 compared with
control (one-way analysis of variance).
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without having an effect on MMP1, MMP13, MMP14,
MMP19 or MMP21 mRNA levels. Although MMP-2
and -3 have also been reported to contribute to breast
tumorigenesis [30], we did not detect MMP2 or MMP3
mRNA expression in cultured MDA-MB-231 cells.
These data demonstrate that the AM9D therapy is spe-
cific as it only affects the production of MMP-9 in cells,
and that reduction of MMP9 mRNA leads to reduction
in enzymatic activity, as expected.
The effect of decreased MMP9 mRNA expression on
the invasive behavior of MDA-MB-231 cells was
assessed by transfecting the cells with fluorescently
labeled AM9D or control DNAzyme and determining
the invasive behavior of the sorted cells using the
ECMatrix™invasion chamber. As shown in Figure 1C,
the mean invasion potential of MDA-MB-231 decreased
by approximately 43% when transfected with AM9D
compared to control DNAzyme-treated cells. These data
are consistent with the reports of others demonstrating
that MMP-9 is one of the key mediators of tumor cell
invasion [11,12,33] and supports the idea of the DNA-
zyme gene-targeted approach for MMP-9 as a breast
cancer therapeutic agent.
MMP-9 is expressed in mammary tumors and the
associated stroma in the MMTV-PyMT model
The MMTV-PyMT transgenic mouse model is a widely
used pre-clinical model of estrogen and progesterone
receptor-negative luminal-like breast cancer with well-
defined stages of progression and metastasis to lung
[34,35]. More importantly, mammary adenocarcinomas
exhibit changes in biomarkers similar to those observed
in patients with breast cancer [34,36]. On a pure FVB/
Nj strain background, all PyMT-positive females will
eventually develop mammary tumors in each of their
ten mammary glands, although the time of tumor onset
varies among individual glands [35]. The expression pat-
terns of various MMPs in the PyMT model [37-39] are
also similar to those observed in patients diagnosed with
ductal mammary adenocarcinoma [40]. Therefore, this
model was chosen to ascertain the role of AM9D as a
pharmacologic inhibitor of MMP-9.
To confirm the presence of MMP-9 protein in late-
stage mammary carcinomas, tumors were harvested
from MMTV-PyMT transgenic females at 12 weeks of
age. Tumor sections were stained with antibodies to
both a-SMA, a marker for stromal myofibroblasts, and
MMP-9. IHC analysis demonstrated the presence of
MMP-9 in the tumor epithelium, including areas highly
populated with stromal fibroblasts (Figure 2). It is also
likely that MMP-9 is produced by the tumor-associated
macrophages that are known to be present in PyMT
tumors [41,42].
DNAzyme is stable in vitro and in vivo and is present in
mammary tumors for at least 14 days post single
intratumoral injection
Prior to testing AM9D for its effect on mammary tumor
growth, the in vivo stability and cellular uptake of naked
DNAzyme molecules was examined by intratumorally
injecting tumor-bearing MMTV-PyMT transgenic
female mice with fluorescently labeled AM9D in PBS.
The animals were then sacrificed at 7, 10, and 14 days
(Figure 3A, a-c) post AM9D injection, and mammary
tumors were harvested, sectioned, and viewed under a
fluorescent microscope. As shown in Figure 3A, fluores-
cently-labeled oligonucleotides could be easily detected
in a diffuse pattern within the tumor for up to 14 days
(Figure 3A, c). Moreover, AM9D could also be detected
in adjacent, non-injected mammary tumors of the same
Figure 2 Immunohistochemical staining for metalloproteinase (MMP)-9 and a-smooth muscle actin (a-SMA) in mammary tumor
sections. Tumors were resected from mice and double stained with antibodies to a-SMA to detect stromal cells (A) and MMP-9 (B). When
channels were merged (C), these data show that MMP-9 was present in both stromal and tumor cells. Magnification 200×; scale bar is
equivalent to 100 µm.
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mouse (Figure 3A, d), indicating a wider distribution
pattern than might be expected from intratumoral injec-
tion. Therefore, the DNAzymes are stable in vivo and
can efficiently distribute within the injected tumor and
to an adjacent non-injected tumor.
To further examine the stability of the DNAzyme in
solution and in vitro, DNAzyme prepared in PBS was
incubated for up to 14 days at 37°C. Aliquots were
removed at different time intervals and the amount and
activity of DNAzyme remaining over time was deter-
mined by applying the DNAzyme to a 6% urea-polyacry-
lamide gel and measuring its ability to cleave a 760 bp
MMP9 RNA substrate (Figure 3B). As demonstrated in
Figure 3B, DNAzyme oligonucleotides are stable in PBS
at 37°C and no significant degradation or loss of enzy-
matic activity was observed over the 14 day period.
The in vitro stability of AM9D was further confirmed
by transfecting MDA-MB-231 cells grown on slides with
fluorescently labeled AM9D as described above, and
visualizing the presence of AM9D in cells by fluorescent
microscope at 24, 48 and 72 hours post transfection. As
shown in Figure 3C, DNAzyme molecules are present in
cells for at least 72 hours post transfection and are
located in both the cytosol and the nucleus. The nucleus
localization significantly increases the effectiveness of
DNAzyme therapy. These data in corroboration with
the in vivo stability of AM9D administered to mammary
tumors of the MMTV-PyMT transgenic mouse (Figure
3A, c-d) demonstrate the retention and potential efficacy
of this therapy.
AM9D treatment reduces final tumor load in the MMTV-
PyMT tumor model
The efficacy of AM9D to reduce breast tumor volume in
MMTV-PyMT transgenic mice was tested by directly
injecting two concentrations (10 or 25 µg) of AM9D or
control DNAzyme into mammary tumors of transgenic
females bearing at least three tumors per mouse, each at
an early palpable size (approximately 3 mm × 5 mm),
once a week for 4 weeks. Tumor palpations were per-
formed weekly to determine changes in tumor volume
over time. The growth rate of AM9D-treated tumors
(n = 12) was slower than both control DNAzyme-treated
tumors (n = 9) and untreated tumors (n = 7) (Figure 4A).
This resulted in a significant reduction in the final tumor
volume of AM9D-treated compared to control DNA-
zyme-treated (P <0.001) and untreated (P <0.01) tumors
at age 12 weeks (Figure 4A). In fact, administration of
AM9D at 10 µg was sufficient to reduce the size of the
tumor by 39.5% (n = 9, P ≤0.01) compared to control
Figure 3 Stability of DNAzyme in mammary tumors, in vitro, and in vivo. (A) Stability of DNAzyme in mammary tumors. Mammary tumors
were injected (as described in Materials and methods) with fluorescently-labeled AM9D and resected at either (a) 7 days, (b) 10 days, or (c) 14
days post-injection; (d) DNAzyme injected into the 2R tumor of a mouse was found to be distributed to an adjacent, non-injected mammary
tumor, 3R, which emerged after intratumoral injections were first initiated. Scale bar is equivalent to 100 µm. (B) Urea-polyacrylamide gel
electrophoresis of cleaved MMP9 RNA by AM9D. AM9D was incubated in PBS at 37ºC for 14 days; an equal amount was removed at days 1, 3, 5,
7, 10, and 14 (1D to 14D, respectively) and incubated with MMP9 RNA substrate at 37ºC for 2 hours. The products were then visualized on a 4%
urea-polyacrylamide gel. Lane 1, RNA substrate alone; lane 2, AM9D without prior incubation at 37°C (0) cleaved RNA substrate into two
fragments. AM9D incubated at 37°C for 1, 3, 5, 7, 10, and 14 days, lanes 3 to 8 respectively, did not lose its catalytic activity toward RNA
substrate. (C) Stability of AM9D in vivo. The MDA-MB-231 cells were transfected with Oregon Green fluorescently labeled AM9D for 72 hours, and
fixed and analyzed for the uptake and stability of AM9D molecule in the cells by fluorescent microscopy (400× magnification). (a) The nucleus is
stained with 4’,6-diamidino-2-phenylindole (DAPI) and (b) AM9D is shown in green. (c) The overlap of AM9D with DAPI staining indicates that
AM9D is present in both the cell cytosol and nuclei, as shown by the arrow.
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(n = 24), which increased to 50% when 25 µg of AM9D
was utilized (n = 21, P ≤0.01) (Figure 4B).
IHC analysis of the mammary tumors (Figure 4C)
confirmed that AM9D treatment successfully downregu-
lated MMP-9 protein expression. As shown in Figure
4C (b), AM9D treatment reduced mean MMP-9 expres-
sion by 66 ± 11% as compared to the control DNAzyme
treatment (Figure 4C, a). This was further confirmed by
the observation that the Mmp9 mRNA levels were 77%
lower in AM9D-treated tumors compared with those
tumors treated with control DNAzyme (Figure 4D).
Taken together, these data show that AM9D efficiently
decreases MMP-9 expression in tumors, resulting in the
observed anti-tumor effects.
AM9D treatment suppresses angiogenesis and stimulates
apoptosis in mammary tumors
MMP-9 has been shown to play a role in tumor progres-
sion through increase of bioavailability of VEGF and
other factors that promote angiogenesis [43]. To deter-
mine the mechanism of tumor volume reduction by
AM9D, the tumor slices were stained for CD-31 and for
activated caspase-3 to assess the effect of AM9D on
angiogenesis and apoptosis, respectively. As shown in
Figure 5A and 5B, AM9D treatment significantly reduced
the number of blood vessels in the tumor as demon-
strated by the lack of robust CD-31 immunostaining in
the AM9D-treated group (Figure 5A, c) versus untreated
(Figure 5A, a) or the control DNAzyme-treated (Figure
5A, b) groups. Moreover, our data also indicate that
AM9D potently induces apoptosis in the tumors, as only
AM9D-treated tumors contained a large number of cas-
pase-3-positive cells, as shown in Figure 5B (b). Quantita-
tive analysis (Figure 5C) indicated that the number of
CD31-positive cells was reduced 5-fold and that the
intensity of the apoptotic cells increased 83-fold in
tumors treated with AM9D compared to controls,
respectively. These data suggest that the simultaneous
Figure 4 Effect of AM9D on the rate of tumor growth, final mean tumor volume, and metalloproteinase (MMP)-9 expression. (A)
AM9D-treated tumors (■) grew at a slower rate than either untreated tumors (no injections) (▼), or tumors treated with control DNAzyme (▲); at
the study endpoint, age 12 weeks, P <0.05. (B) Weekly intratumoral treatment of transgenic mice with 10 µg (n = 9 tumors) or 25 µg AM9D (n =
21 tumors) per tumor reduced mean tumor burden by 39.5% or 50.1%, respectively, when compared to tumors treated with control DNAzyme
(n = 24 tumors) (P <0.01 ANOVA). (C) Mammary tumors treated with either 25 µg AM9D or control DNAzyme were stained with an MMP-9
antibody. (a) Mammary tumors treated with 25 µg control DNAzyme for 4 weeks showed increased MMP-9 staining (arrows) compared to (b)
mammary tumors treated with AM9D for 4 weeks. Images are shown at 200× magnification; scale bar is equivalent to 100 µm. (D) Mmp9 mRNA
expression levels in control DNAzyme- or AM9D-treated tumors. Total RNA was isolated and pooled from optical cutting temperature (OCT)
compound-embedded tumor sections scraped from glass slides of individual control DNAzyme- or AM9D-treated tumors. Mmp9 and Bact (ß-
actin) mRNA were amplified by RT-PCR and the PCR products were subjected to agarose gel and visualized by ethidium bromide staining. Lane
1, AM9D; lane 2, control DNAzyme.
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Figure 5 Angiogenesis and apoptosis immunohistochemical staining of tumors. (A) Staining for CD31 (red) to detect the vasculature in (a)
untreated mammary tumors and mammary tumors harvested from mice treated with (c) 25 µg of AM9D or (b) control DNAzyme. Untreated
tumors (a) and tumors treated with control DNAzyme (b) contained more blood vessels than tumors treated with AM9D (c). Images are shown
at 200× magnification. Scale bar is equivalent to 100 µm. (B) Immunohistochemical staining for caspase-3 to indicate apoptosis in mammary
tumors harvested from mice treated for 4 weeks with (a) control DNAzyme or (b) 25 µg AM9D. Very few caspase-3-positive cells (green) were
detected in tumors treated with control DNAzyme (a) compared to AM9D-treated (b) tumors, where large regions stained positive for caspase-3
(green). Scale bar is equivalent to 100 µm. (C) Histogram showing the mean CD31-immunostained endothelial area and mean apoptotic area in
mammary tumors following treatment with AM9D as compared to untreated tumors and control DNAzyme-treated tumors. *P <0.05 compared
with control (one-way analysis of variance and Student’s t-test).
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anti-angiogenic and pro-apoptotic effect of AM9D delays
tumor growth over time, and decreases tumor volume at
our study endpoint.
Discussion
In this study, we showed for the first time, that the down-
regulation of MMP-9 in mammary tumors by a novel
anti-MMP-9 DNAzyme molecule results in a significant
reduction in final tumor volume in the MMTV-PyMT
transgenic mouse model of breast cancer. Downregula-
tion of MMP-9 by AM9D was accompanied by a
decrease in MMP-9 expression, decreased angiogenesis
and increased apoptosis. Moreover, these effects were
accomplished by intratumoral injection of naked DNA-
zyme without the use of any carriers. AMD9 treatment
also reduced the invasive potential of cultured MDA-
MB-231 cells in vitro (Figure 1C). Together, these data
indicate that specific inhibition of MMP-9 expression by
DNAzyme has potential as a novel therapeutic modality
to decrease the growth and invasion of carcinoma cells in
the clinical setting.
It is known that MMP-9 plays a key role in angiogen-
esis by releasing VEGF [43] and that its downregulation
induces apoptosis by stimulating the ERK pathway [17].
Martin et al. [44] have demonstrated that tumors devel-
oped in MMTV-PyMT MMP-9 wild-type mice are lar-
ger in size and are more highly vascular compared to
those tumors that developed in MMTV-PyMT MMP-9-
null mice. Thus, these data suggest that AM9D treat-
ment affects tumor growth via different pathways, as
downregulation of MMP-9 by AM9D inhibited angio-
genesis and induced apoptosis (Figure 5) as demon-
strated by lack of CD31 staining and the enhanced
presence of caspase-3 in AM9D-treated tumors.
Our results are consistent with those of Almholt et al.
[40] in which the broad-spectrum MMP inhibitor,
Galardin/GM6001, significantly reduced primary mam-
mary tumor growth and lung metastasis in the MMTV-
PyMT model. However, contrary to broad-spectrum
MMP inhibitors, including GM6001, AM9D treatment
specifically downregulates MMP-9 without affecting the
expression of other members of the MMP family. As
demonstrated by the extent of cytoxicity of broad-spec-
trum MMP inhibitors in prior clinical trials [45-47],
total inhibition of MMP is not practical. Various MMPs
can exert both pro-tumorigenic and anti-tumorigenic
properties [48], and some MMPs are critical for normal
physiological processes, such as bone growth and remo-
deling, ovulation, and wound healing [49]. Further, in
comparison with GM6001 [40], the intratumoral injec-
tion of AM9D not only reduced the required frequency
of therapy, but was also equally efficient in reducing
final tumor size. Once weekly, intratumoral injections of
25 µg AM9D (1.25 mg/Kg) was sufficient to reduce the
size of these spontaneously developed tumors by 50% as
compared to the 51% tumor reduction observed follow-
ing daily administration of 100 mg/Kg of GM6001.
Thus, the high degree of specificity of AM9D for target-
ing MMP-9, its in vivo stability, and the lack of any
observed in vivo toxicity (Hallett M, Dalal P, Sweatman
T, Pourmotabbed T: Naked Anti-Matrix Metalloprotei-
nase-9 DNAzyme Administered Systemically Distributes
to All Organs of Healthy and MMTV-PyMT Transgenic
Mice and Is Safe; manuscript in review) should enhance
the clinical response of solid tumors, including breast
tumors, to AM9D treatment, while evading the serious
side effects experienced with systemic therapy based on
broad-spectrum MMP inhibitors.
The MMTV-PyMT transgenic model limited our abil-
ity to assess the efficacy of AM9D on treating sponta-
neous lung metastasis in vivo because not all tumors in
each animal grow synchronously, and thus, not all
tumors were intratumorally treated with therapy. There-
fore, it was not feasible to determine the origin of meta-
static cells (from treated or untreated tumors). The
efficacy of AM9D in inhibiting lung metastasis is under
investigation using a mouse model of metastasis.
Conclusions
Our results indicate that the downregulation of MMP9
mRNA and protein expression with naked anti-MMP-9
DNAzyme is sufficient to reduce mammary tumor burden.
We also describe that tumor size reduction is a result of
decreased MMP-9 expression, decreased angiogenesis, and
increased apoptotic cells in tumors treated with AM9D.
These findings suggest specific targeting and downregula-
tion of MMP-9 by AM9D could prove useful as a therapy
against breast carcinoma tumor growth and invasion.
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